Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715182 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
A Phase 1 study of Advanced/ Metastatic Renal Cell Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 12
- Study locations
NCT00715182 is a Phase 1 study of Advanced/ Metastatic Renal Cell Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 87 participants. The trial reports 12 study locations across 5 states.
The verdict
NCT00715182, a Phase 1 study of Advanced/ Metastatic Renal Cell Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of subjects who have been diagnosed with advanced or metastatic renal cell cancer that is refractory to standard therapy or for which no curative standard therapy exists.
Conditions Studied
Interventions
- DRUG TKI258
Study Locations (12)
Other
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - München
- Novartis Investigative Site - Rotterdam
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Taichung
- Novartis Investigative Site - Taipei
California
- Novartis Investigative Site - San Francisco
North Carolina
- Novartis Investigative Site - Durham
Washington
- Novartis Investigative Site - Seattle
Taiwan, ROC
- Novartis Investigative Site - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00715182
The ClinicalTrials.gov registry entry for NCT00715182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced/ Metastatic Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which TKI258 is the first listed.
NCT00715182 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00715182 about?
NCT00715182 is a clinical study titled "A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer". This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of subjects who have been diagnosed with advanced or metastatic renal cell cancer that is refractory to standard therapy or for...
What is the current status of trial NCT00715182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2008-07. Estimated completion is 2012-07.
What conditions does trial NCT00715182 study?
This clinical trial studies the following conditions: Advanced/ Metastatic Renal Cell Cancer.
What interventions are being tested in trial NCT00715182?
The interventions under investigation include: TKI258 (DRUG).
Who is sponsoring clinical trial NCT00715182?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00715182 being conducted?
This trial has 12 study locations across California, North Carolina, Washington, Taiwan, ROC. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.